Endocrine-Related Cancer

References

1. ↵
   Anderson TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Elles R, Tveit KM, Johnston SR, Dowsett M, Olsen AO, Moller P, Stratton MR & Borresen-Dale AL 1997 Screening for ESR mutations in breast and ovarian cancer patients. Human Mutation 9 531–536.
2. ↵
   Angel P & Karin M 1991 The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochimica et Biophysica Acta 1072 129–157.
3. ↵
   Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM & Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277 965–968.
4. ↵
   Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM & Osborne CK 1993 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment 24 85–95.
5. ↵
   Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D & Norton L 2000 HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. Journal of Clinical Oncology 18 3471–3479.
6. ↵
   Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. Embo J 15 2174–2183.
7. ↵
   Campbell FC, Blamey RW, Elston CW, Morris AH, Nicholson RI, Griffiths K & Haybittle JL 1981 Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 2 1317–1319.
8. ↵
   Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817–9824.
9. ↵
   Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D’Antonio A, Bianco AR & De Placido S 1996 c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Journal of Clinical Oncology 14 2702–2708.
10. ↵
    Chan CM, Lykkesfeldt AE, Parker MG & Dowsett M 1999 Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer. Clinical Cancer Research 5 3460–3467.
11. ↵
    Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y & Evans RM 1997 Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90 569–580.
12. ↵
    Chen JD & Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377 454–457.
13. ↵
    Chung YL, Sheu ML, Yang SC, Lin CH & Yen SH 2002 Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. International Journal of Cancer 97 306–312.
14. ↵
    Clark AS, West K, Streicher S & Dennis PA 2002 Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Molecular Cancer Therapeutics 1 707–717.
15. ↵
    Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM & Dickson RB 1992 Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. Journal of the National Cancer Institute 84 1506–1512.
16. ↵
    Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, Welch JN & Leonessa F 2001 Molecular and pharmacological aspects of antiestrogen resistance. Journal of Steroid Biochemistry and Molecular Biology 76 71–84.
17. ↵
    Coutts AS & Murphy LC 1998 Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Research 58 4071–4074.
18. ↵
    Cui X, Lazard Z, Zhang P, Hopp TA & Lee AV 2003 Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene 22 6937–6941.
19. ↵
    Cui Y, Hopp T & Fuqua SA 2002 A naturally occurring point mutation alters ERα crosstalk with regulatory signaling pathways. San Antonio Breast Cancer Symposium 76 Abstract 168.
20. ↵
    Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S & Boyle P 2003 Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 296–300.
21. ↵
    Datta SR, Brunet A & Greenberg ME 1999 Cellular survival: a play in three Akts. Genes and Development 13 2905–2927.
22. ↵
    De Nardo D, Kim H, Thorn C, Wu K, Lee AV & Brown PH 2003 Estrogen’s ability to stimulate breast cancer growth does not require ER DNA binding. San Antonio Breast Cancer Symposium 82 Abstract 1002.
23. ↵
    De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, Pagliarulo C, Panico L, Pettinato G, Petrella G & Bianco AR 2003 Twenty-year results of the Naples GUN Randomized Trial: Predictive factors of adjavant tamoxifen efficacy in early breast cancer. Clinical Cancer Research 9 1039–1046.
24. ↵
    Dotzlaw H, Leygue E, Watson PH & Murphy LC 1999 Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Research 59 529–532.
25. ↵
    Dowsett M, Houghton J, Baum M, Salter J, A’Hern R, Iden C & Farndon J 1999 ER, PgR, c-ERBB2 and EGFR in patients randomised to adjuvant tamoxifen: combinations of biomarkers as discriminants of treatment benefit. San Antonio Breast Cancer Symposium 57 Abstract 222.
26. ↵
    Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N & Smith I 2001 HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Research 61 8452–8458.
27. ↵
    Dowsett M & Haynes BP 2003 Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. Journal of Steroid Biochemistry and Molecular Biology 86 255–263.
28. ↵
    Dowsett M, Gutierrez C, Moshin S, Schiff R, Detre S, Johnston SR & Osborne CK 2003 Molecular changes in tamoxifen-relapsed breast cancer: Realtionship between ER, HER2 and P38-MAP-kinase, Proceedings of the American Society of Clinical Oncology, 39th Annual Meeting, Chicago, IL, USA. 22 Abstract 7.
29. ↵
    Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA & Cross-Doersen DE 1996 Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth and Differentiation 7 351–359.
30. ↵
    Early Breast Cancer Trialists’ Collaborative Group 1998 Tamoxifen for early breast cancer an overview of the randomised trials. Lancet 351 1451–1467.
31. ↵
    Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E & Borgs M 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor- positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology 19 3808–3816.
32. ↵
    Fahey SM, Tormey DC & Jordan VC 1989 Long-term adjuvant tamoxifen in node-positive breast cancer: A metabolic and pilot clinical study. Breast Cancer Research and Treatment 14 154.
33. ↵
    Font de Mora J & Brown M 2000 AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Molecular and Cellular Biology 20 5041–5047.
34. ↵
    Frasor J, Danes JM, Komm B, Chang KCN, Lyttle R & Katzenellenbogen BS 2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancers cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 4562–4574.
35. ↵
    Fuqua SA, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB, Willson TM & Moore JT 1999 Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Research 59 5425–5428.
36. ↵
    Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM & Allred DC 2003 Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Research 63 2434–2439.
37. ↵
    Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O’Connell P & Allred DC 2000 A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Research 60 4026–4029.
38. ↵
    Gee JM, Robertson JF, Ellis IO & Nicholson RI 2001 Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. International Journal of Cancer 95 247–254.
39. ↵
    Gronemeyer H 1991 Transcription activation by estrogen and progesterone receptors. Annual Review of Genetics 25 89–123.
40. ↵
    Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK & Rosenfeld MG 1997 A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387 43–48.
41. ↵
    Hong SH & Privalsky ML 2000 The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Molecular and Cellular Biology 20 6612–6625.
42. ↵
    Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK et al. 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377 397–404.
43. ↵
    Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A & Morris C 2002 Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 20 3396–3403.
44. ↵
    Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme DH Jr, Windschitl HE, Pfeifle DM, Etzell PS, Gerstner JG, Long HJ et al. 1991 A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer 68 34–39.
45. ↵
    Ito M & Roeder RG The TRAP/SMCC/2001 Mediator complex and thyroid hormone receptor function. Trends in Endocrinology and Metabolism 12 127–134.
46. ↵
    Iwase H, Zhang Z, Omoto Y, Sugiura H, Yamashita H, Toyama T, Iwata H & Kobayashi S 2003 Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer, Chemotherapy and Pharmacology 52 (Suppl 1) S34–S38.
47. ↵
    Jaiyesimi IA, Buzdar AU, Decker DA & Hortobagyi GN 1995 Use of tamoxifen for breast cancer: twenty-eight years later. Journal of Clinical Oncology 13 513–529.
48. ↵
    Jarvinen TA, Pelto-Huikko M, Holli K & Isola J 2000 Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. American Journal of Pathology 156 29–35.
49. ↵
    Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J & Lannigan DA 1998 pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molecular and Cellular Biology 18 1978–1984.
50. ↵
    Johnston SR, Haynes BP, Smith IE, Jarman M, Sacks NP, Ebbs SR & Dowsett M 1993 Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 342 1521–1522.
51. ↵
    Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M & Benz CC 1999 Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clinical Cancer Research 5 251–256.
52. ↵
    Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR & Dowsett M 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Research 55 3331–3338.
53. ↵
    Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R & Grohe C 2000 Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. Journal of Biological Chemistry 275 18447–18453.
54. ↵
    Karnik PS, Kulkarni S, Liu XP, Budd GT & Bukowski RM 1994 Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Research 54 349–353.
55. ↵
    Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H et al. 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 1491–1494.
56. ↵
    Kelly MJ & Levin ER 2001 Rapid actions of plasma membrane estrogen receptors. Trends in Endocrinology and Metabolism 12 152–156.
57. ↵
    Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK & Jo I 1999 Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochemical and Biophysical Research Communications 263 257–262.
58. ↵
    Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB & Rose C 2001 Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. Journal of Clinical Oncology 19 3376–3384.
59. ↵
    Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE & Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine Growth Regulationatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 1032–1044.
60. ↵
    Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary. PNAS 93 5925–5930.
61. ↵
    Kurokawa H & Arteaga CL 2001 Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clinical Cancer Research 7 4411s–4442s.
62. ↵
    Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM & Webb P 2000 Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry and Molecular Biology 74 311–317.
63. ↵
    Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J & Woodgett JR 1994 The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369 156–160.
64. ↵
    Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG & Rose DW 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. PNAS 95 2920–2925.
65. ↵
    Leo C & Chen JD 2000 The SRC family of nuclear receptor coactivators. Gene 245 1–11.
66. ↵
    Leygue E, Dotzlaw H, Watson PH & Murphy LC 1999 Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Research 59 1175–1179.
67. ↵
    Li L, Haynes MP & Bender JR 2003 Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. PNAS 100 4807–4812.
68. ↵
    Lippman ME & Allegra JC 1980 Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46 2829–2834.
69. ↵
    List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A & Riegel AT 2001 Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. Journal of Biological Chemistry 276 23763–23768.
70. ↵
    MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW & Jordan VC 2000 Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Research 60 5097–5105.
71. ↵
    Mahfoudi A, Roulet E, Dauvois S, Parker MG & Wahli W 1995 Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. PNAS 92 4206–4210.
72. ↵
    Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, Li Y & Younes M 2001 Estrogen receptor beta expression in invasive breast cancer. Human Pathology 32 113–118.
73. ↵
    Martens J, Nimmrich I, Koenig T, Look M, Harbeck N & Model F 2003 Epigenetic signature predicts failure of endocrine therapy in patients with recurrent breast cancer. San Antonio Breast Cancer Symposium Abstract 313.
74. ↵
    McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM & Nicholson RI 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142 2776–2788.
75. ↵
    McDonnell DP, Clemm DL, Hermann T, Goldman ME & Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Molecular Endocrinology 9 659–669.
76. ↵
    McKenna NJ, Lanz RB & O’Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocrine Reviews 20 321–344.
77. ↵
    Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Bottero D, Varricchio L, Nanayakkara M, Rotondi A & Auricchio F 2002 Sex steroid hormones act as growth factors. Journal of Steroid Biochemistry and Molecular Biology 83 31–35.
78. ↵
    Mosselman S, Polman J & Dijkema R 1996 ERβ: identification and characterization of a novel human estrogen receptor. FEBS Letters 392 49–53.
79. ↵
    Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL & Evans RM 1997 Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89 373–380.
80. ↵
    New L & Han J 1998 The p38 MAP kinase pathway and its biological function. Trends in Cardiovascular Medicine 8 220–229.
81. ↵
    Newby JC, Johnston SR, Smith IE & Dowsett M 1997 Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clinical Cancer Research 3 1643–1651.
82. ↵
    Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE & Gee JM 2001 Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8 175–182.
83. ↵
    Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Kobayashi S & Iwase H 2001 Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Letters 163 207–212.
84. ↵
    Osborne CK, Coronado E, Allred DC, Wiebe V & DeGregorio M 1991 Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. Journal of the National Cancer Institute 83 1477–1482.
85. ↵
    Osborne CK, Schiff R, Fuqua SA & Shou J 2001 Estrogen receptor: current understanding of its activation and modulation. Clinical Cancer Research 7 4338s–4342s; discussion 4411s–4412s.
86. ↵
    Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R & Buzdar A 2002 Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Journal of Clinical Oncology 20 3386–3395.
87. ↵
    Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353–361.
88. ↵
    Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB & Davidson NE 1994 Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Research 54 2552–2555.
89. ↵
    Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP-1 sites. Science 277 1508–1510.
90. ↵
    Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M & Gustafsson JA 2002 Estrogen receptor beta in breast cancer. Endocrine-Related Cancer 9 1–13.
91. ↵
    Paridaens R, Sylvester RJ, Ferrazzi E, Legros N, Leclercq G & Heuson JC 1980 Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 46 2889–2895.
92. ↵
    Pavlik EJ, Nelson K, Srinivasan S, Powell DE, Kenady DE, DePriest PD, Gallion HH & van Nagell JR Jr 1992 Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Research 52 4106–4112.
93. ↵
    Peto R, Boreham J, Clarke M, Davies C & Beral V 2000 UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 355 1822.
94. ↵
    Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX & Slamon DJ 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 2435–2446.
95. ↵
    Ravdin PM, Fritz NF, Tormey DC & Jordan VC 1988 Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Research 48 1026–1029.
96. ↵
    Razandi M, Pedram A, Park ST & Levin ER 2003 Proximal events in signaling by plasma membrane estrogen receptors. Journal of Biological Chemistry 278 2701–2712.
97. ↵
    Ring A & Dowsett M 2003 Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications. Clinical Breast Cancer 4 (Suppl 1) S34–S41.
98. ↵
    Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD & Parl FF 1995 Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. Journal of the National Cancer Institute 87 446–451.
99. ↵
    Roger P, Sahla ME, Makela S, Gustaffson JA, Baldet P, Rochefort H 2001 Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumours. Cancer Research 61 2537–2541.
100. ↵
     Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M & Hilsenbeck SG 2000 Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumour in vivo. Journal of National Cancer Institute 29 1926–1934.
101. ↵
     Schiff R, Massarweh S, Shou J & Osborne CK 2003 Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clinical Cancer Research 9 447S–454S.
102. ↵
     Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA & Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 927–937.
103. ↵
     Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R & Santen RJ 2000 Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141 396–405.
104. ↵
     Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW & Liao JK 2000 Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 538–541.
105. ↵
     Smith CL, Nawaz Z & O’Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocrinology 11 657–666.
106. ↵
     Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer J-U, Ashley SE, Francis S, Boeddinghams I & Walsh G 2004 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: the IMPACT multicentre double-blind randomised trial. Journal of Clinical Oncology (In Press).
107. ↵
     Speirs V, Malone C, Walton DS, Kerin MJ & Atkin SL 1999 Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Research 59 5421–5424.
108. ↵
     Stal O, Borg A, Ferno M, Kallstrom AC, Malmstrom P & Nordenskjold B 2000 ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Annals of Oncology 11 1545–1550.
109. ↵
     Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z & Flockhart DA 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute 95 1758–1764.
110. ↵
     Stewart J, King R, Hayward J & Rubens R 1982 Estrogen and progesterone receptors: correlation of response rates, site and timing of receptor analysis. Breast Cancer Research Treatment 2 243–250.
111. ↵
     Sudarsanam P & Winston F 2000 The Swi/Snf family nucleosome-remodeling complexes and transcriptional control. Trends in Genetics 16 345–351.
112. ↵
     Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV & Cheng JQ 2001 Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Research 61 5985–5991.
113. ↵
     Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW & McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Molecular Endocrinology 8 21–30.
114. ↵
     Vo N & Goodman RH 2001 CREB-binding protein and p300 in transcriptional regulation. Journal of Biological Chemistry 276 13505–13508.
115. ↵
     Webb P, Lopez GN, Uht RM & Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Molecular Endocrinology 9 443–456.
116. ↵
     Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E, Katzenellenbogen BS, Stallcup MR & Kushner PJ 1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Molecular Endocrinology 12 1605–1618.
117. ↵
     Wolf DM & Jordan VC 1994 The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand-binding domain. Breast Cancer Research Treatment 31 129–138.
118. ↵
     Wong CW, McNally C, Nickbarg E, Komm BS & Cheskis BJ 2002 Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. PNAS 99 14783–14788.
119. ↵
     Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, Tsai MJ & O’Malley BW 2002 Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. Molecular and Cellular Biology 22 3549–3561.
120. ↵
     Zhang CC & Shapiro DJ 2000 Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. Journal of Biological Chemistry 75 479–486.
121. ↵
     Zhang QX, Borg A, Wolf DM, Oesterreich S & Fuqua SA 1997 An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Research 57 1244–1249.